# Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

> **NCT06561243** · — · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Caen** · enrollment: 15000 (estimated)

## Conditions studied

- Chronic B-cell Malignancies
- BTK Inhibitors
- Cardiovascular Diseases

## Interventions

- **DRUG:** BTK inhibitor (Ibrutinib or Acalabrutinib)

## Key facts

- **NCT ID:** NCT06561243
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 15000 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561243, "Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06561243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*